IRulya Therapeutics Inc. (IRLA), a clinical-stage biotechnology company formerly known as Quince Therapeutics, has an unusually wide gap between its share price and the level Wall Street analysts are modeling. The central question for investors is whether a stock trading near $38 can reach roughly $76, a move that would essentially double its value.
The $76 central target is calculated from eight verified analyst price targets: LifeSci Capital at $98, Oppenheimer at $82, Citizens JMP at $77, Raymond James at $72, Rodman & Renshaw at $70, Cantor Fitzgerald at $70, and Craig-Hallum and Leerink Partners at $68 each. The mean is $75.63, rounded to $76, with a range of $68 to $98. All eight current ratings are positive, reflecting a Strong Buy stance; the target is not a guarantee of future performance.
Sentiment improved markedly after the company's May 2026 merger with Orphai Therapeutics refocused the pipeline on LAM-001, an inhaled rapamycin (an mTOR inhibitor, which targets a cellular growth pathway) for pulmonary conditions. Citizens JMP upgraded the stock to Outperform in September 2026, while Raymond James and Rodman & Renshaw initiated coverage in September and October 2026. Cantor Fitzgerald trimmed its target from $80 to $70 in August 2026, a reminder that even bullish firms disagree on valuation.
The stock recently traded near $38, having swung between roughly $30 and $39 in recent weeks and between about $15 and $910 over the past 52 weeks — an extraordinary range for a company whose market capitalization is only in the tens of millions of dollars. Reaching $76 from $38 would require an approximate 100% advance, a very large move that would depend on sustained clinical momentum rather than ordinary price appreciation.
The company generates no meaningful revenue and reported a net loss of roughly $92 million over the trailing twelve months, with EPS (earnings per share) deeply negative. Its investment case rests almost entirely on LAM-001, which is being evaluated for pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome after lung transplant (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH). A Phase 2a study has been completed, with Phase 2 and 2b trials ongoing.
The 52-week trading range of roughly $15 to $910 underscores how volatile this name has been. More recently the stock has consolidated between approximately $30 and $40, with its 50-day moving average near $31 and its 200-day moving average near $33 providing reference levels. A durable move toward $76 would likely require clearing and holding above the upper $30s and low $40s, areas that have acted as resistance. Given the small float, these levels should be treated as zones rather than precise lines.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms may use different frameworks. For IRLA, the most important upcoming items are clinical data readouts for LAM-001 across its PH-ILD, BOS, and SAPH programs, the next earnings report, guidance on cash runway, and any equity financing announcements. Investors should also watch analyst revisions, shifts in short interest, and broader biotech sector risk appetite, which can disproportionately affect small-cap names.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like IRLA, such tools can help traders identify shifting trends, monitor existing positions, and surface opportunities more efficiently than manual scanning alone. Traders can use these signals to complement their own research and stay alert to momentum changes.
The $76 target is a calculated mean of eight analyst price targets, not a forecast of what will happen, and it sits well above the recent price near $38. Reaching it would require a very large, roughly 100% advance driven primarily by successful LAM-001 clinical execution and a favorable funding path. The support is real — a strong cash position and uniformly bullish analyst coverage — but so are the obstacles: no revenue, substantial losses, extreme volatility, and a short-heavy micro-cap structure. The wide $68-to-$98 target range reflects genuine disagreement about the company's clinical odds. Investors should focus on upcoming trial data and cash-position updates rather than treating the target as a certainty.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.